Current aspects of international experience in introducing human papillomavirus vaccination

Authors

  • F.D. Kassymbekova КМУ "ВШОЗ"
  • I.A. Zhetpisbayeva
  • R.S. Dyussenov
  • Zh.M. Zhumanbayeva
  • A.S. Кrykpaeva
  • M.B. Bolatova
  • R.M. Kissina
  • N.E. Glushkova

DOI:

https://doi.org/10.37800/RM.4.2022.7-21

Keywords:

cervical cancer, primary prevention, human papillomavirus vaccination, HPV vaccination implementation

Abstract

Relevance: Despite the existing preventive measures, cervical cancer remains a significant global health problem. More than 80% of cervical cancer cases caused by human papillomavirus (HPV) infection occur in the middle- and low-income countries, where cervical cancer screening and HPV vaccination programs are unavailable or ineffective. HPV vaccination effectively reduces the prevalence of HPV and precancerous lesions and can reduce cervical cancer incidence by 90%. To eliminate cervical cancer worldwide, the World Health Organization has set a goal to vaccinate 90% of girls against HPV by 2030. However, by 2022, only 120 countries (61%) introduced national HPV vaccination programs, and only 15% of the world’s girls had access to HPV vaccination.
The study aimed to examine available literature data on the experience of implementing HPV vaccination in different countries, which can be used to effectively implement and/or improve vaccination program coverage.
Methods: A literature search was carried out simultaneously in the PubMed, Scopus, Google Scholar, and e-Library databases and WHO, CDC, and NCHS websites and covered 2010-2022 publications. The review included 39 articles.
Results: This review summarizes the experience and pace of HPV vaccine introduction in different countries, showing the general principles of determining the target population, vaccination strategy, vaccine and dosing variants, communication, and funding of the program. There is a vivid upward trend in the number of countries, including LMICs, that introduce HPV
vaccination into their national immunization programs. This demonstrates the possibility of overcoming organizational and financial barriers to HPV vaccination. The support of international funds and increased access to the vaccine will reduce the current inequality in access to HPV vaccination.
Conclusion: Using the available experience, countries can successfully introduce HPV vaccination and achieve the necessary results to eliminate cervical cancer worldwide. It is recommended to conduct topical local studies to assess the application of various strategies. This is especially true of the communication process, which often has peculiarities in different countries.

References

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA. Cancer J. Clin. – 2018. – Vol. 68(6). – P. 394-424. https://doi.org/10.3322/caac.21492.

World Health Organization. International agency for cancer research. Cancer Today. Estimated age-standardized incidence rates (World) in 2020, all cancers, sexes, and ages. https://gco.iarc.fr/today/online-analysis-map. 11.10.2022.

Arbyn M., Xu L., Simoens C., Martin-Hirsch P.P.L.; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors // Cochrane database of systematic reviews. – 2018. – Vol. 2018(5). – Art. No.: CD009069. https://doi.org/10.1002/14651858.CD009069.pub3.

Болатбекова Р.О. Новые подходы к диагностике рака шейки матки в Республике Казахстан: дис. … д-р философии (PhD): 6D110100. – НАО Медицинский университет Семей. — Семей: 2018 . — 100 с. [Bolatbekova R.O. Novy`e podkhody` k diagnostike raka shejki matki v Respublike Kazakhstan: dis. … d-r filosofii (PhD): 6D110100. – NAO Medicinskij universitet Semej. — Semej: 2018. — 100 s.] https://www.eruditor.link/file/3278755/.

Simms K.T., Steinberg J., Caruana M., Smith M.A., Lew J.B., Soerjomataram I., Castle P.E., Bray F., Canfell K. Impact of scaled-up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modeling study // Lancet Oncol. – 2019. – Vol. 20(3). – P. 394-407. https://doi.org/10.1016/S1470-2045(18)30836-2.

Villa A., Patton L.L., Giuliano A.R., Estrich C.G., Pahlke S.C., O’Brien K.K., Lipman R.D., Araujo M.W. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews // J. Am. Dent. Assoc. – 2020. – Vol. 151(4). – P. 245-254. https://doi.org/10.1016/J.ADAJ.2019.10.010.

Drolet M., Bénard E., Pérez N., Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis // Lancet. – 2019. – Vol. 394(10197). – P. 497-509. https://doi.org/10.1016/S0140-6736(19)30298-3.

Kjaer S.K., Dehlendorff C., Belmonte F., Baandrup L. Real-World Effectiveness of Human papillomavirus vaccination against cervical cancer // JNCI. – 2021. – Vol. 113(10). – P. 1329-1335. https://doi.org/10.1093/JNCI/DJAB080.

Falcaro M., Castanon A., Ndlela B., Checchi M., Soldan K., Lopez-Bernal J., Elliss-Brookes L., Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study // Lancet. – 2021. – Vol. 398(10316). – P. 2084-2092. https://doi.org/10.1016/S0140-6736(21)02178-4.

Kaidarova D., Chinhissova Z., Bolatbekova R. Implementation of HPV vaccination pilot project in Kazakhstan: Successes and challenges // J. Clin. Oncol. – 2019. – Vol. 37. – P. e13056-e13056. https://doi.org/10.1200/JCO.2019.37.15_suppl.e13056.

World Health Organization. WHO Immunization Data portal. Vaccination coverage globally. https://immunizationdata.who.int. 11.10.2022.

Bruni L., Saura-Lazaro A., Montoliu A., Brotons M., Alemany L., Diallo M.S., Afsar O.Z., LaMontagne D.S., Mosina L., Contreras M., Velandia-González M., Pastore R., Gacic-Dobo M., Bloem M. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019 // Prev. Med. (Baltim). – 2021. – Vol. 144. – Art. No.: 106399. https://doi.org/10.1016/J.YPMED.2020.106399.

Schulein S., Taylor K.J., Konig J., Claus M., Blettner M., Klug S.J. Factors influencing uptake of HPV vaccination among girls in Germany // BMC Public Health. – 2016. – Vol. 16. – Art. No.: 995 (2016). https://doi.org/10.1186/s12889-016-3663-z.

World Health Organization. Weekly Epidemiological Record. – 2009. – Vol. 84 (15). – P. 117-132. https://apps.who.int/iris/handle/10665/241311.

World Health Organization. Weekly epidemiological record. – 2017. – Vol. 92. – P. 241-268. https://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf?sequence=1&isAllowed=y

Barnabas R.V., Brown E.R., Onono M.A., Bukusi E.A., Njoroge B., Winer R.L., Galloway D.A., Pinder L.F., Donnell D., Wakhungu I., Congo O., BiwottCh., Kimanthi S., Oluoch L., Heller K.B., Leingang H., Morrison S., Rechkina E., Cherne S., Schaafsma T.T., McClelland R.S., Celum C., Baeten J.M., Mugo N. for the KEN SHE Study Team. Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women // NEJM Evid. – 2022. – Vol. 1(5). https://doi.org/10.1056/EVIDOA2100056.

World Health Organization. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. News Release, 11.04.2022 //www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer.

Kamolratanakul S., Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer // Vaccines. – 2021. – Vol. 9(12). – Art. No.: 1413. https://doi.org/10.3390/vaccines9121413.

Eliès A., Bonneau C., Houzard S., Rouzier R., Hequet D. Impact of catch-up human papillomavirus vaccination on cervical conization rate in a real-life population in France // PLoS One. – 2022. – Vol. 17(3). – Art. No.: e0264821. https://doi.org/10.1371/journal.pone.0264821.

Freedman M., Kroger A., Hunter P., Ault K.A. Recommended adult immunization schedule, United States, 2020 // Ann. Intern. Med. – 2020. – Vol. 172(5). – P. 337-347. https://doi.org/10.7326/M20-0046.

Weekly epidemiological record. – 2021. – Vol. 96(22). – P. 197-216. https://apps.who.int/iris/handle/10665/341623.

Patel C. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonvalent vaccine prevent? // Euro. Surveillance. – 2018. – Vol. 23(41). – P. 30-40. https://doi.org/10.2807/1560-7917.ES.2018.23.41.1700737.

Principi N., Esposito S. Adolescents and vaccines in the western world // Vaccine. – 2013. – Vol. 31(46). – P. 5366-5374. https://doi.org/10.1016/J.VACCINE.2013.08.092.

Perman S., Turner S., Ramsay A.I.G., Baim-Lance A., Utley M., Fulop N.J. School-based vaccination programs: a systematic review of the evidence on organization and delivery in high-income countries // BMC Public Health. – 2017. – Vol. 17(1). – Art. No.: 252 (2017). https://doi.org/10.1186/S12889-017-4168-0.

Brotherton J.M.L., Winch K.L., Bicknell L., Chappell G., Saville M. HPV vaccine coverage is increasing in Australia // Med. J. Aust. – 2017. – Vol. 206(6). – P. 262-262. https://doi.org/10.5694/MJA16.00958.

Martín-Merino E., Llorente-García A., Castillo Cano B., Montero Corominas D., Huerta-Álvarez C. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval // Pharmaceut. Med. – 2019. – Vol. 33(6). – P. 519-530. https://doi.org/10.1007/S40290-019-00309-9.

Botwright S., Holroyd T., Nanda Sh., Bloem P., Griffiths U.K., Sidibe A., Hutubessy R.C.W. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects // PLoS One. – 2017. – Vol. 12(10). – Art. No.: e0182663. https://doi.org/10.1371/JOURNAL.PONE.0182663.

Dalon F., Majed L., Belhassen M., Jacoud F., Berard M., Levy-Bachelot L., Pouvourville G., Rouzier R., Raude J., Baldauf J.J. Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study // Vaccine. – 2021. – Vol. 39(36). – P. 5129-5137. https://doi.org/10.1016/J.VACCINE.2021.07.054.

Etter D.J., Zimet G.D., Rickert V.I. Human papillomavirus vaccine in adolescent women: A 2012 update // Curr. Opin. Obstet. Gynecol. – 2012. – Vol. 24(5). – P. 305-310. https://doi.org/10.1097/GCO.0B013E3283567005.

Walker T.Y., Eam-Evans L.D., Yankey D., Markowitz L.E., Williams Ch.L., Fredua B., Singleton J.A., Stokley Sh. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017 // MMWR. Morb. Mortal. Wkly. Rep. – 2018. – Vol. 67(33). – P. 909-917. https://doi.org/10.15585/MMWR.MM6733A1.

Widgren K., Simonsen J., Valentiner-Branth P., Molbak K. Uptake of the human papillomavirus vaccination within the free-of-charge childhood vaccination program in Denmark // Vaccine. – 2011. – Vol. 29(52). – P. 9663-9667. https://doi.org/10.1016/J.VACCINE.2011.10.021.

World Health Organization. HPV vaccine program coverage in females. https://app.powerbi.com/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9. 11.10.2022.

Gallagher K.E., Howard N., Kabakama S., Mounier-Jack S., Griffiths U.K., Feletto, Burchett H.E.D., LaMotagne D.S., Watson-Jones D. Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries // PLoS One. – 2017. – Vol. 12(6). – Art. No.: e0177773. https://doi.org/10.1371/JOURNAL.PONE.0177773.

Mphuru A., Li A.J., Kyesi F., Mwengee W., Mazige F., Nshunju R., Shayo B., Giattas M.R., Loharikar A., Lyimo D. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation // Vaccine. – 2022. – Vol. 40(1). – P. A2-A9. https://doi.org/10.1016/J.VACCINE.2021.04.025.

Gallagher K.E., LaMontagne D.S., Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake // Vaccine. – 2018. – Vol. 36(32). – P. 4761-4767. https://doi.org/10.1016/J.VACCINE.2018.02.003.

LaMontagne D.S., Barge S., Le N.T., Mugisha E, Penny M.E., Gandhi S., Janmohamed A., Kumakech E., Mosqueira N.R., Nguyen N.Q., Pau P., Tang Y., Minh T.H., Uttekar B.P., Jumaan A.O. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries // Bull. World Health Organ. – 2011. – Vol. 89(11). – P. 821-830B. https://doi.org/10.2471/BLT.11.089862.

World Health Organization. Systematic literature review of the evidence for effective national immunization schedule promotional communications // – Vol. 23. – 2016. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Literature-reviewnational-immunisation-schedule-promotional-communications.pdf

Thomas T.L. Cancer Prevention: HPV Vaccination HHS Public Access // Semin Oncol Nurs. – 2016. – Vol. 32(3). – P. 273–280. https://doi.org/10.1016/j.soncn.2016.05.007.

Tsu V.D., LaMontagne D.S., Atuhebwe P., Bloem P.N., Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects // Prev. Med. (Baltim). – 2021. – Vol. 144. – Art. No.: 06335. https://doi.org/10.1016/J.YPMED.2020.106335.

Mullins R., Coomber K., Broun K., Wakefield M. Promoting cervical screening after the introduction of the human papillomavirus vaccine: the effect of repeated mass media campaigns // J. Med. Screen. – 2013. – Vol. 20(1). – P. 27-32. https://doi.org/10.1177/0969141313478588.

Bonanni P., Drury R., Joura E.A., Faivre P., Varga S., Bergroth T., Lopalco P.L. The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019) // Expert Rev. Vaccines. – 2020. – Vol. 19(11). – P. 1073-1083. https://doi.org/10.1080/14760584.2020.1858057

Simas C., Munoz N., Arregoces L., Larson H.J. HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia // Hum Vaccin Immunother. – 2019. – Vol. 15(1). – P. 163-166. https://doi.org/10.1080/21645515.2018.1511667.

Larson H. The world must accept that the HPV vaccine is safe // Nature. – 2015. – Vol. 528, no. 7580. – P. 9-9. https://doi.org/10.1038/528009a.

Cody P., Tobe K., Abe M., Elbasha E.H. Public health impact and cost-effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study // BMC Infect. Dis. – 2021. – Vol. 21(1). – Art. No.: 11 (2021). https://doi.org/10.1186/s12879-020-05632-0.

Kunitoki K., Funato M., Mitsunami M., Kinoshita T., Reich M.R. Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence // Vaccine. – 2021. – Vol. 39(41). – P. 6104-6110. https://doi.org/10.1016/J.VACCINE.2021.08.085.

Vorsters A., Bosch F.X., Bonanni P., Franco E.L., Baay M., Simas C., Waheed D.N., Castro C., Murillo R., Trujillo L., Wiesner C., Munoz N. Prevention and control of HPV infection and HPVrelated cancers in Colombia – a meeting report // BMC Proc. – 2020. – Vol. 14(Suppl. 9). – Art. No.: 8(2020). https://doi.org/10.1186/S12919-020-00192-2.

World Health Organization. HPV vaccine communication: special considerations for a unique vaccine. 2016 update. – 2016. – 84 p. https://apps.who.int/iris/bitstream/handle/10665/250279/WHO-IVB-16.02-eng.pdf?sequence=1&isAllowed=y.

Alonso S., Cambaco O., Maússe Y., Matsinhe G., Macete E., Menéndez C., Sicuri E., Sevene E., Munguambe K. Costs associated with delivering HPV vaccination in the context of the first-year demonstration program in southern Mozambique // BMC Public Health. – 2019. – Vol. 19. – P. 2-9. https://doi.org/10.1186/s12889-019-7338-4.

World Health Organization. Market information for access to vaccines. Global Market Study HPV. – March 2022. – P. 1-7. https://cdn.who.int/media/docs/default-source/immunization/mi4a/who-hpvvaccine-global-market-study-April-2022.pdf?sfvrsn=6acb4c98_1&download=true.

Downloads

Published

2022-12-30

How to Cite

[1]
Kassymbekova Ф., Zhetpisbayeva И., Dyussenov Р., Zhumanbayeva Ж., Кrykpaeva А., Bolatova М., Kissina Р. and Glushkova Н. 2022. Current aspects of international experience in introducing human papillomavirus vaccination. Reproductive Medicine. 4(53) (Dec. 2022), 7–21. DOI:https://doi.org/10.37800/RM.4.2022.7-21.

Issue

No. 4(53) (2022): Reproductive medicine

Section

Статьи

License

The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.